Apollomics settles Cayman Islands litigation for $5 million

Apollomics Inc. (NASDAQ: APLM) announced it has reached a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited to resolve litigation filed in the Grand Court of the Cayman Islands.

The dispute involved claims by the two minority shareholders related to the redemption of preferred shares before Apollomics' merger with Maxpro Capital Acquisition Corporation in 2023.

Under the settlement terms, Apollomics will pay TWVC $5 million in cash through installments over two years, plus approximately $879,758 in legal expenses. TWVC originally claimed damages of approximately $40 million, according to the company's Form 20-F filing in April 2025.

The settlement agreement resolves all disputes between the parties. TWVC will withdraw all claims against Apollomics and its affiliates, and both parties are seeking court approval to conclude the litigation proceedings.

Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The company's lead program is vebreltinib, a c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in Phase 2 clinical trials in the United States and other countries.

You May Also Be Interested In